Aeromics, Inc.
Aeromics is a clinical-stage pharmaceutical company focused on developing therapeutics based on a revolutionary understanding of water physiology. Their mission is to control edema by targeting molecular water channels, with the aim of improving patient outcomes in conditions such as stroke, spinal cord injury, CNS surgery, and brain cancer. They are developing an aquaporin-4 inhibitor, AER-271, to prevent or arrest brain swelling following ischemic events, with ongoing clinical trials to evaluate its safety and efficacy.
Industries
Nr. of Employees
small (1-50)
Aeromics, Inc.
Products
Clinical-stage intravenous inhibitor targeting aquaporin-4
A clinical-stage small-molecule therapeutic candidate formulated for intravenous administration to prevent or reduce cerebral edema after ischemic brain injury.
Clinical-stage intravenous inhibitor targeting aquaporin-4
A clinical-stage small-molecule therapeutic candidate formulated for intravenous administration to prevent or reduce cerebral edema after ischemic brain injury.
Services
Expanded access / compassionate use policy
A formal policy to consider providing investigational therapeutics to eligible patients outside of clinical trials.
Expanded access / compassionate use policy
A formal policy to consider providing investigational therapeutics to eligible patients outside of clinical trials.
Expertise Areas
- Neurology therapeutics development
- Cerebral edema and brain swelling therapeutics
- Small-molecule drug discovery and lead optimization
- Early-phase clinical trial management (Phase I/II)
Key Technologies
- Aquaporin-4 targeting
- Small-molecule high-throughput screening
- Lead optimization chemistry
- Intravenous formulation development